QLT Announces Second Quarter 2013 Results

barbara.lempert

VANCOUVER, British Columbia, Aug. 1, (GLOBE NEWSWIRE) — QLT Inc. (Nasdaq:QLTI) (TSX:QLT) (“QLT” or the “Company”) is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. The Company today reported financial for the ended June 30, 2013. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.
2013 SECOND QUARTER FINANCIAL RESULTS
Discontinued Operations Reporting
On September 24, 2012, the Company announced that it completed the sale of its Visudyne® business to Valeant Pharmaceuticals International, Inc. On April 3, 2013, the Company completed the sale of its punctal plug delivery system technology (the “PPDS Technology”) to Mati Therapeutics Inc. In accordance with the accounting standard for discontinued operations, the results of operations relating to both the Visudyne business and the PPDS Technology have been excluded from continuing operations and reported as discontinued operations for the current and prior periods.
QLT Expenses / Other Income
Research and Development (R&D) expenses relate to QLT’s synthetic retinoid program. During the second quarter of 2013, R&D expense was $ 4.4 million compared to $ 7.5 million for the same period in 2012. The $ 3.1 million decrease was primarily due to savings from the Company’s 2012 restructuring initiatives and higher spending in 2012 related to the completion of certain early stage safety studies and manufacturing activities required to support clinical studies.
During the second quarter of 2013, Selling, General and Administrative (SG&A) expense was $ 1.8 million compared to $ 5.9 million for the same period in 2012. The $ 4.1 million decrease was primarily due to savings from the Company’s 2012 restructuring initiatives.
Investment and Other Income was $ 1.2 million…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS